A Multicenter, Randomized, Double-Blind, Phase II/III Study of BCA101 or Placebo in Combination with Pembrolizumab for First Line Treatment of PD-L1-positive, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
II/III

ClinicalTrials.gov Identifier:
NCT06788990

Study #:
STUDY00161544

Start Date:
Aug 22, 2025

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06788990

View Complete Trial Details & Eligibility at ClinicalTrials.gov